Evidence map›Paper›PMID 31915983›Full record

ArticleInternational journal of colorectal disease2020

Clinical assessment of risk factors for infection in inflammatory bowel disease patients.

Joan Tosca, Natalia Garcia, Isabel Pascual, Marta Maia Bosca-Watts, Rosario Anton, Ana Sanahuja, Pilar Mas, Francisco Mora, Miguel Minguez

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of colorectal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Joan ToscaDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain. joantosca@gmail.com.ORCID http://orcid.org/0000-0003-1258-9513
Natalia GarciaDigestive Medicine department, Hospital de Manises, Avda. de la Generalitat Valenciana, 50, 46940, Manises, Valencia, Spain.
Isabel PascualDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Marta Maia Bosca-WattsDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Rosario AntonDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Ana SanahujaDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Pilar MasDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Francisco MoraDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Miguel MinguezDigestive Medicine department, Hospital Clínic Universitari de Valencia, Universitat de Valencia, Avda. Blasco Ibañez, 17, 46010, Valencia, Spain.
Universitat de València · ESGeneralitat Valenciana · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecognizing patients with inflammatory bowel disease who are prone to infection would enable the adjustment of the type and intensity of immunosuppressive treatment. The aim of this study was to identify a clinical profile of risk for infections in IBD patients, based on the interaction of immunosuppressive treatment with factors inherent to the patient.

methodsA case-control study was performed among patients older than 18 years. Patients with any significant infection (any kind of severe or recurrent infection according to standard clinical criteria or a critical enough infection according to the patient) were defined as cases. Both cases and controls were randomly selected in a 1:3 ratio. All the period from diagnosis to the end of recruitment (June 2016) was analyzed. Risk factors for infection were identified by logistic regression analysis; the strength of association was reported by odds ratio (OR) with 95% confidence interval (95%CI).

resultsA total of 112 cases and 270 controls were included. The independent risk factors for significant infection are the number of immunosuppressants (one drug: OR 1.28, 95% CI 0.53-3.11, two drugs: OR 2.37, 95% CI 1.01-5,56, and three drugs: OR 5.84, 95% CI 1.57-21.72), body mass index (OR 1.08; 95 %CI 1,01-1,16), the degree of comorbidity (OR 1.52; 95% CI 1.04-2.21), and the intensity of inflammatory activity (OR 1.43; 95% CI 1.19-1.71).

conclusionsRegardless of immunosuppression, several patient factors such as comorbidity, body mass index, or the inflammatory activity of the disease determine the individual risk of infectious complications and should be considered for an adequate risk assessment.

Indexed as

Body Mass IndexCase-Control StudiesDisease SusceptibilityHumansImmunosuppressive AgentsInfectionsInflammatory Bowel DiseasesRisk FactorsImmunosuppressive AgentsImmunosuppressive treatmentInfectious diseaseRisk factors

Identifiers

PMID31915983
OpenAlexW2999880523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.